Department of Immunology, H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA.
J Immunol. 2010 Mar 15;184(6):3106-16. doi: 10.4049/jimmunol.0902661. Epub 2010 Feb 8.
Ag-specific T cell tolerance plays a critical role in tumor escape. Recent studies implicated myeloid-derived suppressor cells (MDSCs) in the induction of CD8(+) T cell tolerance in tumor-bearing hosts. However, the mechanism of this phenomenon remained unclear. We have found that incubation of Ag-specific CD8(+) T cells, with peptide-loaded MDSCs, did not induce signaling downstream of TCR. However, it prevented subsequent signaling from peptide-loaded dendritic cells. Using double TCR transgenic CD8(+) T cells, we have demonstrated that MDSC induced tolerance to only the peptide, which was presented by MDSCs. T cell response to the peptide specific to the other TCR was not affected. Incubation of MDSCs with Ag-specific CD8(+) T cells caused nitration of the molecules on the surface of CD8(+) T cells, localized to the site of physical interaction between MDSC and T cells, which involves preferentially only TCR specific for the peptide presented by MDSCs. Postincubation with MDSCs, only nitrotyrosine-positive CD8(+) T cells demonstrated profound nonresponsiveness to the specific peptide, whereas nitrotyrosine-negative CD8(+) T cells responded normally to that stimulation. MDSCs caused dissociation between TCR and CD3zeta molecules, disrupting TCR complexes on T cells. Thus, these data describe a novel mechanism of Ag-specific CD8(+) T cell tolerance in cancer.
抗原特异性 T 细胞耐受在肿瘤逃逸中起着关键作用。最近的研究表明,髓系来源的抑制细胞(MDSCs)在肿瘤宿主中诱导 CD8(+)T 细胞耐受中起作用。然而,这种现象的机制尚不清楚。我们发现,用负载肽的 MDSC 孵育抗原特异性 CD8(+)T 细胞不会诱导 TCR 下游的信号转导。然而,它阻止了随后来自负载肽的树突状细胞的信号转导。使用双 TCR 转基因 CD8(+)T 细胞,我们已经证明 MDSC 仅诱导对由 MDSC 呈递的肽的耐受。对另一个 TCR 特异性肽的 T 细胞反应不受影响。MDSC 与抗原特异性 CD8(+)T 细胞孵育会导致 CD8(+)T 细胞表面分子的硝化,这些分子定位于 MDSC 和 T 细胞之间物理相互作用的部位,这主要涉及仅针对由 MDSC 呈递的肽的 TCR。与 MDSC 孵育后,只有硝基酪氨酸阳性的 CD8(+)T 细胞对特定肽表现出明显的无反应性,而硝基酪氨酸阴性的 CD8(+)T 细胞对该刺激正常反应。MDSC 导致 TCR 和 CD3zeta 分子分离,破坏 T 细胞上的 TCR 复合物。因此,这些数据描述了癌症中抗原特异性 CD8(+)T 细胞耐受的一种新机制。